"Tumor Burden" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
| Descriptor ID |
D047368
|
| MeSH Number(s) |
E05.041.124.892
|
| Concept/Terms |
Tumor Burden- Tumor Burden
- Burden, Tumor
- Tumor Load
- Load, Tumor
- Loads, Tumor
- Tumor Loads
Tumor Weight- Tumor Weight
- Tumor Weights
- Weight, Tumor
- Weights, Tumor
|
Below are MeSH descriptors whose meaning is more general than "Tumor Burden".
Below are MeSH descriptors whose meaning is more specific than "Tumor Burden".
This graph shows the total number of publications written about "Tumor Burden" by people in this website by year, and whether "Tumor Burden" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 6 | 6 |
| 2010 | 1 | 6 | 7 |
| 2011 | 1 | 9 | 10 |
| 2012 | 1 | 5 | 6 |
| 2013 | 0 | 11 | 11 |
| 2014 | 3 | 15 | 18 |
| 2015 | 1 | 14 | 15 |
| 2016 | 2 | 22 | 24 |
| 2017 | 1 | 13 | 14 |
| 2018 | 0 | 11 | 11 |
| 2019 | 2 | 11 | 13 |
| 2020 | 0 | 13 | 13 |
| 2021 | 0 | 8 | 8 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Burden" by people in Profiles.
-
Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease. J Clin Oncol. 2024 Oct 10; 42(29):3387-3391.
-
Uterine Inflammatory Myofibroblastic Tumors: p16 as a Surrogate for CDKN2A Deletion and Predictor of Aggressive Behavior. Am J Surg Pathol. 2024 Jul 01; 48(7):813-824.
-
Clinical Significance of Pheochromocytoma Size on the Timing and Extent of Surgery. J Surg Res. 2024 Jun; 298:88-93.
-
Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 Jul; 35(7):989-997.e2.
-
Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2024 May; 35(5):712-721.e3.
-
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. Lung Cancer. 2023 12; 186:107417.
-
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
-
Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS Comput Biol. 2022 02; 18(2):e1009822.
-
Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models. Biomed Pharmacother. 2022 Mar; 147:112662.
-
FZD10-targeted a-radioimmunotherapy with 225 Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model. Cancer Sci. 2022 Feb; 113(2):721-732.